---
document_datetime: 2025-12-02 04:52:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/qdenga.html
document_name: qdenga.html
version: success
processing_time: 0.1216877
conversion_datetime: 2025-12-29 22:31:29.08674
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Qdenga

[RSS](/en/individual-human-medicine.xml/67636)

##### Authorised

This medicine is authorised for use in the European Union

dengue tetravalent vaccine (live, attenuated) Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Qdenga](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77864)
- [More information on Qdenga](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Qdenga is a vaccine that helps protect against dengue disease. The vaccine can be given to adults, adolescents and children from 4 years of age.

Dengue disease is a mosquito-borne tropical disease caused by the dengue virus, leading to mild, flu-like symptoms in most people. However, a small number of patients develop severe disease, with potentially fatal bleeding and organ damage.

This vaccine contains attenuated (weakened) versions of dengue virus serotypes (varieties) 1, 2, 3 and 4.

Expand section

Collapse section

## How is Qdenga used?

This vaccine can only be obtained with a prescription and should be used in accordance with official recommendations.

The vaccine is given as an injection under the skin of the upper arm. The vaccination course consists of 2 injections given 3 months apart.

For more information about using this vaccine, see the package leaflet or contact your healthcare provider.

## How does Qdenga work?

Dengue disease is caused by infection with dengue virus, which is transmitted to humans through the bite of mosquitos. This vaccine contains attenuated versions of the 4 virus serotypes. These versions cannot cause the disease, but they 'teach' the immune system (the body's natural defences) to defend the body against the virus.

When a person is given the vaccine, the immune system identifies the attenuated serotypes as foreign and makes antibodies against them. When a person is later exposed to the virus, the immune system recognises it and can quickly make many more antibodies, which then neutralise the virus before it can cause dengue disease.

## What benefits of Qdenga have been shown in studies?

This vaccine was shown to be effective at preventing fever due to dengue disease in children and adolescents in the 12 months following the second injection. In a main study in 8 countries in Latin America and the Asia Pacific region, about 20,000 children between the age of 4 to 16 years were given Qdenga or placebo (a dummy injection). The study showed a reduction by 80% in the number of fever cases caused by confirmed dengue disease in those who received the vaccine (61 cases in 12,700 children) compared with those given placebo (149 cases in 6,316 children). The vaccine also reduced hospitalisation due to dengue by 90%. In the 18 months after receiving the second injection, 0.1% (13 out of 12,700) of children given the vaccine were hospitalised because of confirmed dengue, compared with 1.0% (66 out of 6,316) of children given placebo.

## What are the risks associated with Qdenga?

The most common side effects with Qdenga (which may affect more than 1 in 5 people) are pain and redness at the injection site, headache, muscle pain, feeling generally unwell and weakness. Up to 1 in 10 people may experience fever. These side effects, which are usually of mild to moderate severity and resolve within a few days, are less frequent after the second dose of the vaccine than after the first.

This vaccine must not be used in people who had a hypersensitivity (allergic) reaction to a previous dose of Qdenga. It must also not be used in individuals with a weakened immune system because of a disease, medicines that affect the immune system or HIV infection. The vaccine must not be used in women who are pregnant or breastfeeding.

For the full list of side effects and restrictions of Qdenga, see the package leaflet.

## Why is Qdenga authorised in the EU?

Qdenga provides protection against fever and hospitalisation resulting from dengue disease caused by any of the 4 dengue virus serotypes. Side effects are mostly mild to moderate in severity and disappear within a few days.

The European Medicines Agency therefore decided that Qdenga's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Qdenga?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Qdenga have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Qdenga are continuously monitored. Suspected side effects reported with Qdenga are carefully evaluated and any necessary action taken to protect patients.

## Other information about Qdenga

Qdenga received a marketing authorisation valid throughout the EU on 5 December 2022.

Qdenga : EPAR - Medicine Overview

Reference Number: EMA/861969/2022

English (EN) (105.37 KB - PDF)

**First published:** 16/12/2022

[View](/en/documents/overview/qdenga-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-801)

български (BG) (144.04 KB - PDF)

**First published:**

16/12/2022

[View](/bg/documents/overview/qdenga-epar-medicine-overview_bg.pdf)

español (ES) (120.88 KB - PDF)

**First published:**

16/12/2022

[View](/es/documents/overview/qdenga-epar-medicine-overview_es.pdf)

čeština (CS) (151.08 KB - PDF)

**First published:**

16/12/2022

[View](/cs/documents/overview/qdenga-epar-medicine-overview_cs.pdf)

dansk (DA) (121.09 KB - PDF)

**First published:**

16/12/2022

[View](/da/documents/overview/qdenga-epar-medicine-overview_da.pdf)

Deutsch (DE) (125.7 KB - PDF)

**First published:**

16/12/2022

[View](/de/documents/overview/qdenga-epar-medicine-overview_de.pdf)

eesti keel (ET) (107.3 KB - PDF)

**First published:**

16/12/2022

[View](/et/documents/overview/qdenga-epar-medicine-overview_et.pdf)

ελληνικά (EL) (147.14 KB - PDF)

**First published:**

16/12/2022

[View](/el/documents/overview/qdenga-epar-medicine-overview_el.pdf)

français (FR) (122.26 KB - PDF)

**First published:**

16/12/2022

[View](/fr/documents/overview/qdenga-epar-medicine-overview_fr.pdf)

hrvatski (HR) (139.87 KB - PDF)

**First published:**

16/12/2022

[View](/hr/documents/overview/qdenga-epar-medicine-overview_hr.pdf)

italiano (IT) (120.08 KB - PDF)

**First published:**

16/12/2022

[View](/it/documents/overview/qdenga-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (156.91 KB - PDF)

**First published:**

16/12/2022

[View](/lv/documents/overview/qdenga-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (149 KB - PDF)

**First published:**

16/12/2022

[View](/lt/documents/overview/qdenga-epar-medicine-overview_lt.pdf)

magyar (HU) (151.05 KB - PDF)

**First published:**

16/12/2022

[View](/hu/documents/overview/qdenga-epar-medicine-overview_hu.pdf)

Malti (MT) (142.69 KB - PDF)

**First published:**

16/12/2022

[View](/mt/documents/overview/qdenga-epar-medicine-overview_mt.pdf)

Nederlands (NL) (121.79 KB - PDF)

**First published:**

16/12/2022

[View](/nl/documents/overview/qdenga-epar-medicine-overview_nl.pdf)

polski (PL) (146.71 KB - PDF)

**First published:**

16/12/2022

[View](/pl/documents/overview/qdenga-epar-medicine-overview_pl.pdf)

português (PT) (121.64 KB - PDF)

**First published:**

16/12/2022

[View](/pt/documents/overview/qdenga-epar-medicine-overview_pt.pdf)

română (RO) (140.55 KB - PDF)

**First published:**

16/12/2022

[View](/ro/documents/overview/qdenga-epar-medicine-overview_ro.pdf)

slovenčina (SK) (153.03 KB - PDF)

**First published:**

16/12/2022

[View](/sk/documents/overview/qdenga-epar-medicine-overview_sk.pdf)

slovenščina (SL) (149.8 KB - PDF)

**First published:**

16/12/2022

[View](/sl/documents/overview/qdenga-epar-medicine-overview_sl.pdf)

Suomi (FI) (117.84 KB - PDF)

**First published:**

16/12/2022

[View](/fi/documents/overview/qdenga-epar-medicine-overview_fi.pdf)

svenska (SV) (119.21 KB - PDF)

**First published:**

16/12/2022

[View](/sv/documents/overview/qdenga-epar-medicine-overview_sv.pdf)

Qdenga : EPAR - Risk Management Plan

English (EN) (1.41 MB - PDF)

**First published:** 16/12/2022

**Last updated:** 11/12/2024

[View](/en/documents/rmp/qdenga-epar-risk-management-plan_en.pdf)

## Product information

Qdenga : EPAR - Product Information

English (EN) (631.99 KB - PDF)

**First published:** 16/12/2022

**Last updated:** 19/08/2025

[View](/en/documents/product-information/qdenga-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-9)

български (BG) (1 MB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/bg/documents/product-information/qdenga-epar-product-information_bg.pdf)

español (ES) (627.55 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/es/documents/product-information/qdenga-epar-product-information_es.pdf)

čeština (CS) (1021.74 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/cs/documents/product-information/qdenga-epar-product-information_cs.pdf)

dansk (DA) (639.51 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/da/documents/product-information/qdenga-epar-product-information_da.pdf)

Deutsch (DE) (665.67 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/de/documents/product-information/qdenga-epar-product-information_de.pdf)

eesti keel (ET) (627.97 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/et/documents/product-information/qdenga-epar-product-information_et.pdf)

ελληνικά (EL) (1.07 MB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/el/documents/product-information/qdenga-epar-product-information_el.pdf)

français (FR) (666.59 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/fr/documents/product-information/qdenga-epar-product-information_fr.pdf)

hrvatski (HR) (948.35 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/hr/documents/product-information/qdenga-epar-product-information_hr.pdf)

íslenska (IS) (995.67 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/is/documents/product-information/qdenga-epar-product-information_is.pdf)

italiano (IT) (650.89 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/it/documents/product-information/qdenga-epar-product-information_it.pdf)

latviešu valoda (LV) (994.4 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/lv/documents/product-information/qdenga-epar-product-information_lv.pdf)

lietuvių kalba (LT) (991.29 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/lt/documents/product-information/qdenga-epar-product-information_lt.pdf)

magyar (HU) (913.56 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/hu/documents/product-information/qdenga-epar-product-information_hu.pdf)

Malti (MT) (978.66 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/mt/documents/product-information/qdenga-epar-product-information_mt.pdf)

Nederlands (NL) (674.83 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/nl/documents/product-information/qdenga-epar-product-information_nl.pdf)

norsk (NO) (573.68 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/no/documents/product-information/qdenga-epar-product-information_no.pdf)

polski (PL) (1.02 MB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/pl/documents/product-information/qdenga-epar-product-information_pl.pdf)

português (PT) (653.32 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/pt/documents/product-information/qdenga-epar-product-information_pt.pdf)

română (RO) (994.12 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/ro/documents/product-information/qdenga-epar-product-information_ro.pdf)

slovenčina (SK) (1.04 MB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/sk/documents/product-information/qdenga-epar-product-information_sk.pdf)

slovenščina (SL) (922.7 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/sl/documents/product-information/qdenga-epar-product-information_sl.pdf)

Suomi (FI) (1013.85 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/fi/documents/product-information/qdenga-epar-product-information_fi.pdf)

svenska (SV) (641.56 KB - PDF)

**First published:**

16/12/2022

**Last updated:**

19/08/2025

[View](/sv/documents/product-information/qdenga-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** EMEA/H/W/WS2809 17/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Qdenga : EPAR - All authorised presentations

English (EN) (83.07 KB - PDF)

**First published:** 16/12/2022

[View](/en/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-848)

български (BG) (101.11 KB - PDF)

**First published:**

16/12/2022

[View](/bg/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_bg.pdf)

español (ES) (81.71 KB - PDF)

**First published:**

16/12/2022

[View](/es/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_es.pdf)

čeština (CS) (65.61 KB - PDF)

**First published:**

16/12/2022

[View](/cs/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (84.14 KB - PDF)

**First published:**

16/12/2022

[View](/da/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (86.74 KB - PDF)

**First published:**

16/12/2022

[View](/de/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (81.99 KB - PDF)

**First published:**

16/12/2022

[View](/et/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (100.95 KB - PDF)

**First published:**

16/12/2022

[View](/el/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_el.pdf)

français (FR) (82.49 KB - PDF)

**First published:**

16/12/2022

[View](/fr/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (142.58 KB - PDF)

**First published:**

16/12/2022

[View](/hr/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (83.05 KB - PDF)

**First published:**

16/12/2022

[View](/is/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_is.pdf)

italiano (IT) (93.3 KB - PDF)

**First published:**

16/12/2022

[View](/it/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (126.59 KB - PDF)

**First published:**

16/12/2022

[View](/lv/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (131.07 KB - PDF)

**First published:**

16/12/2022

[View](/lt/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (101.01 KB - PDF)

**First published:**

16/12/2022

[View](/hu/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (104.32 KB - PDF)

**First published:**

16/12/2022

[View](/mt/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (82.46 KB - PDF)

**First published:**

16/12/2022

[View](/nl/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (122.22 KB - PDF)

**First published:**

16/12/2022

[View](/no/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_no.pdf)

polski (PL) (131.53 KB - PDF)

**First published:**

16/12/2022

[View](/pl/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_pl.pdf)

português (PT) (82.2 KB - PDF)

**First published:**

16/12/2022

[View](/pt/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_pt.pdf)

română (RO) (124.74 KB - PDF)

**First published:**

16/12/2022

[View](/ro/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (118.13 KB - PDF)

**First published:**

16/12/2022

[View](/sk/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (124.83 KB - PDF)

**First published:**

16/12/2022

[View](/sl/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (108.25 KB - PDF)

**First published:**

16/12/2022

[View](/fi/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (82.57 KB - PDF)

**First published:**

16/12/2022

[View](/sv/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Qdenga Active substance

- Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated
- Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated
- Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated
- Dengue virus, serotype 2, live, attenuated

International non-proprietary name (INN) or common name dengue tetravalent vaccine (live, attenuated) Therapeutic area (MeSH) Dengue Anatomical therapeutic chemical (ATC) code J07BX04

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age.

The use of Qdenga should be in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/005155

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Takeda GmbH

Byk-Gulden-Strasse 2

Opinion adopted 13/10/2022 Marketing authorisation issued 05/12/2022 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Qdenga : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (181.71 KB - PDF)

**First published:** 06/06/2024

**Last updated:** 08/07/2025

[View](/en/documents/procedural-steps-after/qdenga-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Qdenga-H-C-PSUSA-00011034-202408 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/226035/2025

English (EN) (149.03 KB - PDF)

**First published:** 08/07/2025

[View](/en/documents/scientific-conclusion/qdenga-h-c-psusa-00011034-202408-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Qdenga-H-C-PSUSA-00011034-202308 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/264016/2024

English (EN) (90.86 KB - PDF)

**First published:** 06/06/2024

[View](/en/documents/scientific-conclusion/qdenga-h-c-psusa-00011034-202308-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Qdenga : EPAR - Public assessment report

Adopted

Reference Number: EMA/862552/2022

English (EN) (11.62 MB - PDF)

**First published:** 16/12/2022

[View](/en/documents/assessment-report/qdenga-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Qdenga

Adopted

Reference Number: EMA/CHMP/781052/2022

English (EN) (99.41 KB - PDF)

**First published:** 14/10/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-qdenga_en.pdf)

#### News on Qdenga

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022) 14/10/2022

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Qdenga : EPAR - Product information - tracked changes

English (EN) (389.22 KB - DOCX)

**First published:** 08/07/2025

[View](/en/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-922)

български (BG) (345.44 KB - DOCX)

**First published:**

08/07/2025

[View](/bg/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_bg.docx)

español (ES) (338.98 KB - DOCX)

**First published:**

08/07/2025

[View](/es/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_es.docx)

čeština (CS) (336.81 KB - DOCX)

**First published:**

08/07/2025

[View](/cs/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (342.73 KB - DOC)

**First published:**

08/07/2025

[View](/da/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_da.doc)

Deutsch (DE) (345.65 KB - DOCX)

**First published:**

08/07/2025

[View](/de/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (346.44 KB - DOCX)

**First published:**

08/07/2025

[View](/et/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (361.58 KB - DOCX)

**First published:**

08/07/2025

[View](/el/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_el.docx)

français (FR) (346.44 KB - DOCX)

**First published:**

08/07/2025

[View](/fr/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (369.58 KB - DOCX)

**First published:**

08/07/2025

[View](/hr/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (508.04 KB - DOCX)

**First published:**

08/07/2025

[View](/is/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_is.docx)

italiano (IT) (347.12 KB - DOCX)

**First published:**

08/07/2025

[View](/it/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (336.04 KB - DOCX)

**First published:**

08/07/2025

[View](/lv/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (346.51 KB - DOCX)

**First published:**

08/07/2025

[View](/lt/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (362.35 KB - DOCX)

**First published:**

08/07/2025

[View](/hu/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (326.17 KB - DOCX)

**First published:**

08/07/2025

[View](/mt/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (345.79 KB - DOCX)

**First published:**

08/07/2025

[View](/nl/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (442.46 KB - DOCX)

**First published:**

08/07/2025

[View](/no/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_no.docx)

polski (PL) (341.19 KB - DOCX)

**First published:**

08/07/2025

[View](/pl/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_pl.docx)

português (PT) (336.99 KB - DOCX)

**First published:**

08/07/2025

[View](/pt/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_pt.docx)

română (RO) (339.34 KB - DOCX)

**First published:**

08/07/2025

[View](/ro/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (335.99 KB - DOCX)

**First published:**

08/07/2025

[View](/sk/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (333.14 KB - DOCX)

**First published:**

08/07/2025

[View](/sl/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (476.75 KB - DOCX)

**First published:**

08/07/2025

[View](/fi/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (349.25 KB - DOCX)

**First published:**

08/07/2025

[View](/sv/documents/product-information-tracked-changes/qdenga-epar-product-information-tracked-changes_sv.docx)

#### More information on Qdenga

- [EMEA-001888-PIP01-15-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001888-pip01-15-m02)
- [DEN-401: The Association Between Prior Exposure to Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and Dengue Hospitalization in a Pediatric and Adolescent Population: A Nested Case-Control Post-Authorization Effectiveness Study - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000218)

**This page was last updated on** 19/08/2025

## Share this page

[Back to top](#main-content)